March/April 2012

Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.

Two initiatives currently under way will support the generation of new insight into the safety of medicines and treatment effectiveness.

An activity-based cost accounting model of melanoma care was used to identify key cost drivers and opportunities for stakeholder innovation.

Because the increasing prevalence of atrial fibrillation imposes significant financial and clinical burdens, efficient healthcare delivery is required to improve outcomes and reduce associated costs.

The conversation between physician and patient when medication is prescribed is important and the incorrect use of medications has health and cost implications.

For the majority of children and adolescents receiving a psychotropic medication there is a valid medical diagnosis.